Q3 EPS Estimates for FocalTherics Increased by HC Wainwright

FocalTherics (NASDAQ:FOCL) – Equities research analysts at HC Wainwright raised their Q3 2026 earnings per share estimates for FocalTherics in a report issued on Tuesday, August 25th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.17) for the quarter, up from their previous estimate of ($0.22). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for FocalTherics’ current full-year earnings is ($0.78) per share. HC Wainwright also issued estimates for FocalTherics’ Q4 2026 earnings at ($0.20) EPS, FY2026 earnings at ($0.82) EPS, Q1 2027 earnings at ($0.15) EPS, Q2 2027 earnings at ($0.11) EPS, Q3 2027 earnings at ($0.15) EPS, Q4 2027 earnings at ($0.06) EPS, FY2027 earnings at ($0.47) EPS, FY2028 earnings at ($0.04) EPS, FY2029 earnings at $0.05 EPS and FY2030 earnings at $0.25 EPS.

Several other research firms also recently weighed in on FOCL. Piper Sandler reaffirmed a “neutral” rating and set a $4.00 price target on shares of FocalTherics in a research note on Friday, August 14th. Wall Street Zen cut FocalTherics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Mizuho set a $15.00 price objective on FocalTherics and gave the stock an “outperform” rating in a report on Friday, July 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of FocalTherics in a research report on Monday, August 17th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $7.75.

FocalTherics Price Performance

FocalTherics stock opened at $4.41 on Thursday. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.38 and a current ratio of 1.60. The stock has a market cap of $165.51 million, a PE ratio of -4.28 and a beta of -0.04. The firm has a 50-day moving average of $5.32. FocalTherics has a 1 year low of $1.50 and a 1 year high of $6.40.

FocalTherics (NASDAQ:FOCL) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.19). FocalTherics had a negative return on equity of 248.00% and a negative net margin of 56.26%.The company had revenue of $13.20 million during the quarter.

Institutional Investors Weigh In On FocalTherics

A number of institutional investors have recently added to or reduced their stakes in FOCL. Rock Springs Capital Management LP raised its holdings in FocalTherics by 7.1% in the first quarter. Rock Springs Capital Management LP now owns 1,378,000 shares of the company’s stock worth $5,126,000 after purchasing an additional 91,500 shares in the last quarter. Lido Advisors LLC bought a new position in shares of FocalTherics during the 1st quarter worth approximately $40,000. SmartHarvest Portfolios LLC bought a new position in shares of FocalTherics during the 1st quarter worth approximately $38,000. Flax Pond Capital LLC purchased a new stake in FocalTherics during the fourth quarter valued at approximately $2,623,000. Finally, Kovack Advisors Inc. purchased a new stake in FocalTherics during the fourth quarter valued at approximately $53,000. Institutional investors own 62.74% of the company’s stock.

Insider Buying and Selling

In related news, Director David R. Horn bought 10,000 shares of the stock in a transaction on Friday, August 14th. The stock was bought at an average price of $4.75 per share, for a total transaction of $47,500.00. Following the completion of the acquisition, the director directly owned 10,000 shares in the company, valued at approximately $47,500. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Lance Willsey bought 50,000 shares of the company’s stock in a transaction on Friday, August 14th. The shares were bought at an average cost of $4.75 per share, for a total transaction of $237,500.00. Following the transaction, the director directly owned 1,291,780 shares in the company, valued at approximately $6,135,955. This represents a 4.03% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 116,000 shares of company stock valued at $551,000 over the last ninety days. Company insiders own 10.10% of the company’s stock.

Key FocalTherics News

Here are the key news stories impacting FocalTherics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and a $10 price target, implying substantial upside from the reported $4.41 reference price. The firm also raised its FY2027 EPS estimate to a loss of $0.47 from $0.54 and improved estimates for the third quarter of 2026 and the first three quarters of 2027. HC Wainwright Reiterates Buy Rating for FocalTherics
• Positive Sentiment: The analyst projects continued earnings improvement over the longer term, forecasting smaller losses in FY2028 and profitability of $0.05 per share in FY2029 and $0.25 per share in FY2030. These estimates support the longer-term growth case for FOCL. HC Wainwright FocalTherics Earnings Estimates
• Neutral Sentiment: Reported short interest was listed at zero shares, producing a zero-day short-interest ratio. Because the figures show no meaningful short position, they offer little evidence of either short-covering support or bearish pressure.
• Negative Sentiment: HC Wainwright reduced its FY2026 EPS estimate to a loss of $0.82 from $0.78 and expects a $0.20-per-share loss in the fourth quarter. FocalTherics is already loss-making, with a recent quarterly EPS miss and negative net margin, so near-term profitability and execution remain key risks.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.